PPARγ and atherosclerosis

ABSTRACT Background: Peroxisome proliferator-activated receptor (PPAR)γ regulates a number of cellular processes that affect glucose homeostasis, endothelial function and vessel wall inflammation, as well as protecting against cardiovascular complications that occur in diabetes. Thiazolidinediones are PPARγ agonists that are in clinical use for the treatment of type 2 diabetes. Accumulating evidence indicates that thiazolidinediones may exert cardioprotective effects at each stage of atherogenesis. Scope: This paper reviews preclinical and clinical evidence (identified from a search of MEDLINE databases) supporting a beneficial cardiovascular effect of thiazolidinediones and discusses the implications of these data for the optimal use of thiazolidinediones in clinical practice. Findings: In vitro animal model and clinical studies indicate that thiazolidinediones correct endothelial dysfunction, suppress chronic inflammatory processes, reduce fatty streak formation, delay plaque evolution and vessel wall thickening and enhance plaque stabilization and regression. Conclusion: Thus, thiazolidinediones show potential as potent anti-inflammatory, antithrombotic agents that could both improve glucose levels and the long-term cardiovascular risk related to atherosclerosis in patients with type 2 diabetes.

[1]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[2]  W. Hsueh,et al.  Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[3]  N. Marx,et al.  Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.

[4]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[5]  B. Staels,et al.  Peroxisome proliferator‐activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages , 2002, FEBS letters.

[6]  C. Tack,et al.  Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects , 1998, Diabetes Care.

[7]  T. Kato,et al.  Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. , 2001, Metabolism: clinical and experimental.

[8]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[9]  F. Logerfo,et al.  The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. , 2003, Metabolism: clinical and experimental.

[10]  A. Aljada,et al.  Evidence for a potent antiinflammatory effect of rosiglitazone. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  J. Cooke,et al.  The role of nitric oxide in atherosclerosis. , 1999, Coronary artery disease.

[12]  M. Quon,et al.  Inhibition of Phosphatidylinositol 3-Kinase Enhances Mitogenic Actions of Insulin in Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[13]  Y. Jang,et al.  Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. , 2004, Diabetes care.

[14]  John Dormandy,et al.  The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. , 2004, Diabetes care.

[15]  M. D. Leibowitz,et al.  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. , 1996, Biochemical and biophysical research communications.

[16]  A. Baron,et al.  Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. , 2002, Diabetes.

[17]  Tzung-Dau Wang,et al.  Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.

[18]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[19]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[20]  A. Aljada,et al.  Troglitazone Reduces Reactive Oxygen Species Generation by Leukocytes and Lipid Peroxidation and Improves Flow-Mediated Vasodilatation in Obese Subjects , 2000, Hypertension.

[21]  D. Accili,et al.  Increased CD36 protein as a response to defective insulin signaling in macrophages. , 2004, The Journal of clinical investigation.

[22]  V. Fuster,et al.  The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[23]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[24]  U. Garbin,et al.  Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. , 1997, Free radical biology & medicine.

[25]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[26]  S. Jo,et al.  Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone , 2004, Journal of Biological Chemistry.

[27]  J. Kaski,et al.  The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.

[28]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[29]  peterlibby,et al.  CD40 Signaling and Plaque Instability , 2001 .

[30]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[31]  E. Fleck,et al.  Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor &ggr; in Vascular Smooth Muscle Cells , 2003, Circulation research.

[32]  J. Panza,et al.  Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus , 2002, Circulation.

[33]  M. D. Leibowitz,et al.  Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .

[34]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[35]  J. Kaski,et al.  Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. , 2004, The American journal of cardiology.

[36]  B. Staels,et al.  Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells , 2002, Journal of cardiovascular pharmacology.

[37]  B. Miskin,et al.  The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus , 2001, Coronary artery disease.

[38]  Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus , 2002 .

[39]  H. Parving,et al.  Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.

[40]  U. Garbin,et al.  Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. , 1994, Diabetes research.

[41]  S. Mathur,et al.  PPAR&ggr; Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice , 2004, Hypertension.

[42]  D. Einhorn,et al.  Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. , 2000, Clinical therapeutics.

[43]  原口 剛.  PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptor , 2003 .

[44]  J. Reckless,et al.  Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. , 2004, Diabetes care.

[45]  Daniel Steinberg,et al.  Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.

[46]  G. Jennings,et al.  Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-&ggr; Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation , 2003, Circulation.

[47]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[48]  T. Ishida,et al.  Thiazolidinedione inhibits the production of monocyte chemoattractant protein‐1 in cytokine‐treated human vascular endothelial cells , 1999, FEBS letters.

[49]  Jennifer Tuepker.  Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. , 2003, Circulation.

[50]  P. Moghetti,et al.  Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control , 1995, Diabetologia.

[51]  G. Assmann,et al.  The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. , 1988, American heart journal.

[52]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[53]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[54]  T. Yoshimoto,et al.  Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. , 1999, Atherosclerosis.

[55]  P. Anderson,et al.  Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. , 2001, International immunopharmacology.

[56]  Petr Jarolim,et al.  Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.

[57]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[58]  M. Stumvoll,et al.  Glitazones: clinical effects and molecular mechanisms , 2002, Annals of medicine.

[59]  J. Roman,et al.  Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[60]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[61]  W. A. Bradley,et al.  PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. , 2003, Journal of lipid research.

[62]  Richard T. Lee,et al.  Pathophysiology of atherosclerotic plaque development and rupture: an overview. , 2003, Seminars in vascular medicine.

[63]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[64]  E. Fleck,et al.  PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. , 1999, Journal of cardiovascular pharmacology.

[65]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[66]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[67]  P. Fitzgerald,et al.  Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. , 2004, American heart journal.

[68]  M. Quon,et al.  Insulin stimulates both endothelin and nitric oxide activity in the human forearm. , 1999, Circulation.

[69]  S. Verga,et al.  Plasma endothelin levels in NIDDM patients with macroangiopathy. , 1994, Diabetes research.

[70]  K. Shimada,et al.  Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. , 1999, Atherosclerosis.

[71]  T. Akasaka,et al.  Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. , 2000, Journal of the American College of Cardiology.

[72]  E. Fleck,et al.  A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. , 2003, European journal of pharmacology.

[73]  M. Kawano,et al.  Increased Plasma Levels of Immunoreactive Endothelin and von Willebrand Factor In NIDDM Patients , 1995, Diabetes Care.

[74]  T. Nakamura,et al.  Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. , 2000, Journal of diabetes and its complications.

[75]  K. Tanabe,et al.  Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. , 2003, American heart journal.

[76]  E. Ferrannini,et al.  Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients , 1998, Diabetes.